Orphan Medical Will Launch Sucraid For Sucrase Deficiency In June
Orphan Medical will launch Sucraid (sacrosidase) for treatment of the genetic disorder CSID in early June.
You may also be interested in...
QOL Medical’s Sucraid Is First To Lose Its REMS
In the brief history of Risk Evaluation and Mitigation Strategies, QOL Medical’s enzyme replacement therapy Sucraid stands out for the unusual reason behind the REMS requirements in the first place, and because it was the first and only product to date to be released from its risk management obligations.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011